<DOC>
	<DOCNO>NCT01604811</DOCNO>
	<brief_summary>Inflammation report one recent hypotheses explain BPH . Recent publish work point urine serum marker could use detection prostatic inflammation . The aim study ass activity inflammation biomarkers ( serum urine inflammation marker ) Permixon® 160 mg hard capsule Tamsulosine Arrow LP treatment urinary symptom relate BPH . The potential link serum urinary marker inflammation BPH clinical symptom baseline treatment explore .</brief_summary>
	<brief_title>Exploratory Study L.S.E.S.r . ( LipidoSterolic Extract Serenoa Repens ) ( PERMIXON® 160 mg Hard Capsule ) Versus Tamsulosine LP Activity Inflammation Biomarkers Urinary Symptoms Related BPH ( Benign Prostatic Hyperplasia )</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Permixon</mesh_term>
	<criteria>Male patient Between 45 85 year old . Patient bothersome low urinary tract symptom pollakiuria ( daytime night time ) , urgency , sensation incomplete voiding , delay urination weak stream , exist 12 month IPSS ≥ 10 selection visit ≥ 12 randomisation visit ( visit 2 ) Stable patient 's disease randomisation define absolute difference 2 less IPSS selection randomisation visit ( visit 1 visit 2 ) IPSS QoL score ≥ 3 evaluated selection randomisation visit , 5 mL/s ≤ maximum urinary flow rate &lt; 15 mL/s void volume ≥ 150 mL ≤ 500 mL evaluate randomisation visit ( 2 measurement necessary ) Prostatic volume ≥30 cm³ determine transrectal ultrasound randomisation visit ( visit 2 ) Serum total PSA randomisation visit ( visit 2 ) : 4 ng/mL 10 ng/mL Prostate Specific Antigen ( free ) / Prostate Specific Antigen ( total ) ≥ 25 % negative prostate biopsy within past 6 month prior selection visit . Patient able understand sign inform consent understand fill selfquestionnaires Postvoid residual urine volume &gt; 200 mL ( suprapubic ultrasound ) randomisation visit ( visit 2 ) . Urological history : Urethral stricture disease and/or bladder neck disease Active ( selection randomisation visit ) recent ( &lt; 3 month ) recurrent urinary tract infection Indication BPH surgery Stone bladder urethra Acute chronic ( document ) prostatitis Prostate cancer cancer treat untreated Interstitial cystitis ( document symptom and/or biopsy ) Active upper tract stone disease cause symptoms Patient history surgery prostate , bladder neck pelvic region Any local and/or systemic inflammation disorder selection randomisation visit</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>